Literature DB >> 3263272

Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts.

K Khazaie1, T J Dull, T Graf, J Schlessinger, A Ullrich, H Beug, B Vennström.   

Abstract

The transforming capacity of the normal and mutant human EGF receptor (EGFR) was investigated in primary chicken cells. In fibroblasts, both N- and C-terminal truncations resulted in a weak, additive oncogenic activity. However, not even double truncations caused a v-erbB-like phenotype. Upon EGF-binding, on the other hand, both normal and C-terminally truncated EGFRs resembled v-erbB in their fibroblast transforming potential. In erythroblasts, N-terminal truncation was sufficient to induce constitutive self-renewal, which was enhanced by deletion of 32 C-terminal amino acids but abolished by a larger truncation of 202 amino acids. In contrast to the normal EGFR, the receptor lacking 32 C-terminal amino acids resembled v-erbB in conferring erythropoietin independence for spontaneous differentiation to the transformed erythroblasts. Our results indicate that the C-terminal domain of the EGFR is non-essential in fibroblast transformation, but seems to be crucial for both self renewal induction and specificity of receptor function in erythroblasts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263272      PMCID: PMC454693          DOI: 10.1002/j.1460-2075.1988.tb03171.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

1.  The transforming activity of the chicken c-myc gene can be potentiated by mutations.

Authors:  L Frykberg; T Graf; B Vennström
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

2.  v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation.

Authors:  P Kahn; L Frykberg; C Brady; I Stanley; H Beug; B Vennström; T Graf
Journal:  Cell       Date:  1986-05-09       Impact factor: 41.582

3.  Monoclonal antibodies to novel erythroid differentiation antigens reveal specific effects of oncogenes on the leukaemic cell phenotype.

Authors:  J A Schmidt; J Marshall; M J Hayman; G Doderlein; H Beug
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

4.  c-erbB activation in ALV-induced erythroblastosis: novel RNA processing and promoter insertion result in expression of an amino-truncated EGF receptor.

Authors:  T W Nilsen; P A Maroney; R G Goodwin; F M Rottman; L B Crittenden; M A Raines; H J Kung
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  Analysis of the autophosphorylation activity of transformation defective mutants of avian erythroblastosis virus.

Authors:  M J Hayman; G Kitchener; J Knight; J McMahon; R Watson; H Beug
Journal:  Virology       Date:  1986-04-15       Impact factor: 3.616

6.  Rous-associated virus 1-induced erythroleukemic cells exhibit a weakly transformed phenotype in vitro and release c-erbB-containing retroviruses unable to transform fibroblasts.

Authors:  H Beug; M J Hayman; M B Raines; H J Kung; B Vennström
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

7.  Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus.

Authors:  A Johnsson; C Betsholtz; C H Heldin; B Westermark
Journal:  Nature       Date:  1985 Oct 3-9       Impact factor: 49.962

8.  Susceptibility to erbB-induced erythroblastosis is a dominant trait of 151 chickens.

Authors:  H L Robinson; B D Miles; D E Catalano; W E Briles; L B Crittenden
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

9.  Activation of c-erbB in avian leukosis virus-induced erythroblastosis leads to the expression of a truncated EGF receptor kinase.

Authors:  I Lax; R Kris; I Sasson; A Ullrich; M J Hayman; H Beug; J Schlessinger
Journal:  EMBO J       Date:  1985-12-01       Impact factor: 11.598

10.  Purification and characterization of cMGF, a novel chicken myelomonocytic growth factor.

Authors:  A Leutz; H Beug; T Graf
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

View more
  35 in total

1.  Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen.

Authors:  M Papetti; I M Herman
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Multiple functions of let-23, a Caenorhabditis elegans receptor tyrosine kinase gene required for vulval induction.

Authors:  R V Aroian; P W Sternberg
Journal:  Genetics       Date:  1991-06       Impact factor: 4.562

3.  The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation.

Authors:  L Naldini; E Vigna; R Ferracini; P Longati; L Gandino; M Prat; P M Comoglio
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

4.  Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor).

Authors:  A Mondino; S Giordano; P M Comoglio
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

Review 5.  Structure and function of tyrosine kinase receptors.

Authors:  M F White
Journal:  J Bioenerg Biomembr       Date:  1991-02       Impact factor: 2.945

6.  Ectopic expression of the erythrocyte band 3 anion exchange protein, using a new avian retrovirus vector.

Authors:  S Fuerstenberg; H Beug; M Introna; K Khazaie; A Muñoz; S Ness; K Nordström; J Sap; I Stanley; M Zenke
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Developmentally regulated use of alternative promoters creates a novel platelet-derived growth factor receptor transcript in mouse teratocarcinoma and embryonic stem cells.

Authors:  T H Vu; G R Martin; P Lee; D Mark; A Wang; L T Williams
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

8.  Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels.

Authors:  M Cotten; F Längle-Rouault; H Kirlappos; E Wagner; K Mechtler; M Zenke; H Beug; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

9.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09

10.  Epidermal growth factor-receptor mutant lacking the autophosphorylation sites induces phosphorylation of Shc protein and Shc-Grb2/ASH association and retains mitogenic activity.

Authors:  N Gotoh; A Tojo; K Muroya; Y Hashimoto; S Hattori; S Nakamura; T Takenawa; Y Yazaki; M Shibuya
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.